Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: Interim results from phase III, extension study 307

Adjunctive perampanel for refractory partial-onset seizures: Randomized phase III study 304

(2012) J. A. French et al.   NEUROLOGY

Randomized phase III study 306: Adjunctive perampanel for refractory partial-onset seizures

(2012) G. L. Krauss et al.   NEUROLOGY

Tolerability and safety of perampanel: two randomized dose-escalation studies

(2011) G. L. Krauss et al.   ACTA NEUROLOGICA SCANDINAVICA

Perampanel: A novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy

(2011) Takahisa Hanada et al.   EPILEPSIA

The pharmacological treatment of epilepsy in adults

(2011) Emilio Perucca et al.   LANCET NEUROLOGY

Revisiting AMPA Receptors as an Antiepileptic Drug Target

(2011) Michael A. Rogawski   Epilepsy Currents

Long-term efficacy and safety of eslicarbazepine acetate: Results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy

(2010) Peter Halász et al.   EPILEPSIA

Minimizing AED Adverse Effects: Improving Quality of Life in the Interictal State in Epilepsy Care

(2009) Erik St. Louis   Current Neuropharmacology

Long-term safety and efficacy of zonisamide in patients with refractory partial-onset epilepsy

(2008) S. J. Wroe et al.   ACTA NEUROLOGICA SCANDINAVICA